Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2025 08:30 ET | Source: Aptose Biosciences, Inc.

Aptose Common Shares to Delist from Nasdaq as of April 2, 2025

Nasdaq to Delist Aptose Common Shares as of April 2, 2025
March 28, 2025 08:01 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Year End 2024 Results and Corporate Highlights

Aptose Reports Year End 2024 Results and Corporate Highlights
March 17, 2025 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
February 20, 2025 07:32 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort

Aptose Announces Positive Clinical Safety Review and Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib
February 18, 2025 16:30 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Reverse Share Split

Aptose Announces Reverse Share Split
February 13, 2025 16:30 ET | Source: Aptose Biosciences, Inc.

Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility

Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
February 12, 2025 07:00 ET | Source: Aptose Biosciences, Inc.

Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial

Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
January 09, 2025 16:00 ET | Source: Aptose Biosciences, Inc.

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
December 19, 2024 16:05 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Positive Decision by Nasdaq Hearings Panel

Aptose Announces Positive Decision by Nasdaq Hearings Panel
December 12, 2024 10:15 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells

Next Page keyboard_arrow_right